Literature DB >> 22869130

Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.

Jichun Ma1, Wai Kwan Tang, Lothar Esser, Ira Pastan, Di Xia.   

Abstract

The mesothelin-specific monoclonal antibody MORAb-009 is capable of blocking the binding of mesothelin to CA-125 and displays promising anticancer potential. It is currently undergoing clinical trials. In order to understand the basis of the interaction between MORAb-009 and mesothelin at atomic resolution, both the Fab fragment of MORAb-009 and the complex between the Fab and an N-terminal fragment of mesothelin (residues 7-64) were crystallized. The crystals of the Fab diffracted X-rays to 1.75 Å resolution and had the symmetry of space group P4(1)2(1)2, with unit-cell parameters a = b = 140.6, c = 282.0 Å. The crystals of the mesothelin-Fab complex diffracted to 2.6 Å resolution and belonged to the hexagonal space group P6(4), with unit-cell parameters a = b = 146.2, c = 80.9 Å. Structural analyses of these molecules are in progress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869130      PMCID: PMC3412781          DOI: 10.1107/S1744309112028229

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  20 in total

1.  Improving antibody affinity by mimicking somatic hypermutation in vitro.

Authors:  P S Chowdhury; I Pastan
Journal:  Nat Biotechnol       Date:  1999-06       Impact factor: 54.908

2.  Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes.

Authors:  Z Che; N H Olson; D Leippe; W M Lee; A G Mosser; R R Rueckert; T S Baker; T J Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

4.  Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.

Authors:  A C Bateman; R K al-Talib; T Newman; J H Williams; A Herbert
Journal:  Histopathology       Date:  1997-01       Impact factor: 5.087

5.  Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.

Authors:  Mitchell Ho; Raffit Hassan; Jingli Zhang; Qing-Cheng Wang; Masanori Onda; Tapan Bera; Ira Pastan
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

6.  Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.

Authors:  Armin Rump; Yoshihiro Morikawa; Minoru Tanaka; Sawako Minami; Naohiko Umesaki; Masaki Takeuchi; Atsushi Miyajima
Journal:  J Biol Chem       Date:  2003-12-15       Impact factor: 5.157

7.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Molecular cloning and expression of megakaryocyte potentiating factor cDNA.

Authors:  T Kojima; M Oh-eda; K Hattori; Y Taniguchi; M Tamura; N Ochi; N Yamaguchi
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

9.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

Review 10.  CA 125: the past and the future.

Authors:  R C Bast; F J Xu; Y H Yu; S Barnhill; Z Zhang; G B Mills
Journal:  Int J Biol Markers       Date:  1998 Oct-Dec       Impact factor: 3.248

View more
  5 in total

1.  Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.

Authors:  Tatsuya Hanaoka; Kosei Hasegawa; Tomomi Kato; Sho Sato; Akira Kurosaki; Akiko Miyara; Shoji Nagao; Hiroyuki Seki; Masanori Yasuda; Keiichi Fujiwara
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

Review 2.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.

Authors:  Gwendlyn Kollmorgen; Klara Palme; Annette Seidl; Stefan Scheiblich; Fabian Birzele; Sabine Wilson; Christian Clemens; Edgar Voss; Martin Kaufmann; Klaus Hirzel; Natascha Rieder; Ben-Fillippo Krippendorff; Frank Herting; Gerhard Niederfellner
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

4.  Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.

Authors:  Emily Kolyvas; Michael Rudloff; Marianne Poruchynsky; Rebekah Landsman; Kevin Hollevoet; David Venzon; Christine Alewine
Journal:  Oncotarget       Date:  2017-02-07

5.  Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids.

Authors:  Jian-Ming Lü; Zhengdong Liang; Dongliang Liu; Bin Zhan; Qizhi Yao; Changyi Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.